NCT02910739View on ClinicalTrials.gov

An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

April 3, 2017

Study Completion Date

April 12, 2017

Conditions
Amnestic Mild Cognitive ImpairmentAlzheimer's DiseaseProdromal Alzheimer's Disease
Interventions
DRUG

MK-8931

MK-8931 40 mg

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02910739 - An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) | Biotech Hunter | Biotech Hunter